The JP Morgan presentation may have had a bit to do with it. As always Mike presented incredibly well and IMV put pay to many of the assumptions that had been made around GLP1 using what seemed like factual data. Whether these fact were selective may need to be tested but some points I picked up from my first lesson.
- Growth can be expected although he wasn't going to quote results prior to official release.
- The market is massive, increasing in size and Resmeds products are a long way in front in terms of what they deliver
- GLP1 drugs are proving to provide incremental sales for Resmed, improving compliance and peripheral repurchase (they have at least 2 years worth of data on this if i recall correctly).
Agree or disagree, Mick put the points well and supported them with data, not hearsay, not assumptions. Happy to stay invested based on what I heard and Im sure it would have been a catalyst to buy for some
Well worth a listen. Its on the Quartr App.
Or it may just be a run up to a results release sell off....
GLAH
The JP Morgan presentation may have had a bit to do with it. As...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$34.72 |
Change
-0.790(2.22%) |
Mkt cap ! $22.04B | |||
| Open | High | Low | Value | Volume |
| $34.95 | $34.95 | $34.61 | $25.63M | 736.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 484 | $34.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $34.73 | 1408 | 9 |
View Market Depth
| Last trade - 11.42am 02/10/2024 (20 minute delay) ? |
| RMD (ASX) Chart |